174 patents
Page 4 of 9
Utility
High concentration anti-C5 antibody formulations
21 Jun 22
The present disclosure relates to stable aqueous solutions comprising a high concentration of an anti-C5 antibody (e.g., ravulizumab) and methods for preparing the solutions.
Stephan Ortiz, Jillian Gentile, Leena Philominathan, Eric Routhier, Bruce Mason
Filed: 27 Jul 18
Utility
Manufacturing of alkaline phosphatases
7 Jun 22
A method for producing a recombinant polypeptide, comprising: (a) providing a 100 L to 25,000 L fed-batch bioreactor comprising (i) cells capable of expressing the recombinant polypeptide asfotase alfa (SEQ ID NO: 1), and (ii) a culture medium suitable for conducting such expression, the culture medium comprising about 25 μM to about 300 μM zinc; (b) culturing the cells under conditions suitable to express the recombinant asfotase alfa wherein the pH of the culture medium is about 6.7 to about 7.1, and wherein zinc is added into said culture medium such that the zinc concentration in the culture medium is maintained at a concentration of about 25 μM to about 300 μM of zinc.
Pratik Jaluria, Siguang Sui
Filed: 16 Aug 16
Utility
Monovalent Anti-properdin Antibodies and Antibody Fragments
26 May 22
Described herein are isolated monovalent antibodies or antibody fragments thereof that bind human properdin.
Douglas L. SHERIDAN, Paul P. TAMBURINI, Taneisha Ann-Tanara MACK, Walter C. VOEGTLI
Filed: 9 Nov 21
Utility
Synthesis of cerdulatinib
24 May 22
Anjali Pandey, Arvinder Sran, Ying Chen, Daniele Poggiali, Tiziano Fumagalli
Filed: 21 Oct 20
Utility
Methods for Treating Intracranial Hemorrhage and Assessing Efficacy
28 Apr 22
The present disclosure relates to compositions and methods useful for assessing the efficacy in a patient having suffered from intracranial hemorrhage while undergoing an anticoagulation treatment with a factor Xa (fXa) inhibitor.
Patrick Yue
Filed: 7 Feb 20
Utility
ANTI-ALK2 Antibodies and Uses Thereof
31 Mar 22
Provided herein are antibodies that bind to activin receptor—like kinase 2 (ALK2) and are useful for treating bone disorders, such as those involving reduced bone mineral density and bone mineralization defects, and promoting bone growth.
Jeffrey William Hunter, Julian Chandler, Keith Bouchard, Andre Marozsan, Patricia Bento, Anjli Kukreja
Filed: 5 Dec 19
Utility
Process for Making Recombinant Antidote to Factor Xa Inhibitor
31 Mar 22
Disclosed are methods and isolated cells useful for the improved production of function fXa derivative protein that acts as a fXa inhibitor antidote.
Genmin Lu, Pamela B. Conley, Uma Sinha
Filed: 28 Jul 21
Utility
Cerdulatinib for the Treatment of B-cell Malignancies
31 Mar 22
Provided herein are compositions and methods for treating a relapsed or refractory hematologic cancer in a human patient in need thereof.
Anjali Pandey, Gregory Coffey, Janet Leeds
Filed: 10 May 21
Utility
Methods for Preparing Ammonium Tetrathiomolybdate
17 Mar 22
This disclosure relates to crystalline ammonium tetrathiomolybdate having pharmaceutical grade purity and processes for manufacturing crystalline ammonium tetrathiomolybdate.
Viveca Oltner, Niklas Wahlstrom
Filed: 14 Jan 20
Utility
Methods for treating lymphoma
8 Mar 22
Compositions and methods for treating lymphoma, in particular, T-cell lymphoma and follicular lymphoma, in a human patient are provided.
Gregory Coffey, Matthew Birrell, Pamela B. Conley, John T. Curnutte, Anjali Pandey, Andrew Steele, Glenn Michelson
Filed: 3 May 19
Utility
Bone delivery conjugates and method of using same to target proteins to bone
15 Feb 22
A bone delivery conjugate having a structure selected from the group consisting of: A) X-Dn-Y-protein-Z; and B) Z-protein-Y-Dn-X, wherein X is absent or is an amino acid sequence of at least one amino acid; Y is absent or is an amino acid sequence of at least one amino acid; Z is absent or is an amino acid sequence of at least one amino acid; and Dn is a poly aspartate wherein n=10 to 16.
Philippe Crine, Guy Boileau, Isabelle Lemire, Thomas P. Loisel
Filed: 28 Dec 18
Utility
Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
8 Feb 22
This invention provides, inter alia, a complement-inhibitor-based treatment plan coupled with a risk evaluation and management strategy (“REMS”) and a safety support program (“SSP”) for reinforcing the REMS.
Leonard Bell, Camille Bedrosian
Filed: 6 Jun 17
Utility
Lysosomal acid lipase deficiency compositions and methods
1 Feb 22
Compositions and methods relating to potentially pathogenic mutations in the nucleotide sequence of a human LIPA gene.
Andrew Hutchinson, John V. W. Reynders, Guillermo del Angel, Nina Jain, Christen D. Forbes, Xiao-Qin Ren, Barbara Burton
Filed: 16 Jun 17
Utility
Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
25 Jan 22
A method of treating a human having a condition or disease related to a bone defect characterized by at least one of: increased level of an alkaline phosphatase ligand, particularly PPi, PLP, or PEA; and decreased alkaline phosphatase activity, compared to a human without said condition or disease, comprising administering to the human a therapeutically effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide is administered through at least one subcutaneous injection to the human in a frequency of fewer than three times each week.
Rajendra Pradhan, Xiang Gao
Filed: 27 Sep 16
Utility
Methods for treating hypophosphatasia (HPP) in adults and adolescents
18 Jan 22
The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., an adult having HPP, such as an adult having pediatric-onset HPP, or an adolescent having HPP) exhibiting decreased pyrophosphate (PPi) or pyridoxal 5′-phosphate (PLP) concentrations in, e.g., a plasma sample, physical impairments, or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient.
Scott Edward Moseley, Andrew E. Denker, Wei-Jian Pan
Filed: 29 Mar 18
Utility
Treating seizure with recombinant alkaline phosphatase
18 Jan 22
The present disclosure provides a method of treating seizure in a subject having aberrant alkaline phosphatase activities, comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to the subject.
Andre Marozsan, Denise Devore, Susan Liu-Chen
Filed: 18 Oct 19
Utility
Fusion Proteins and Methods of Treating Complement Dysregulation Using the Same
13 Jan 22
Described herein are fusion proteins that include two fragments of factor H, a fragment of factor H and an Fc domain, or a fragment of factor H, a fragment of CR2, and an Fc domain.
Julian Chandler, Christian Cobaugh, Keith Bouchard, Jeffrey Hunter
Filed: 22 Aug 19
Utility
Methods for Treatment of Refractory Generalized Myasthenia Gravis In Pediatric Patients
6 Jan 22
The disclosure provides methods of treating myasthenia gravis (MG) in a pediatric subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (CS).
Róisín ARMSTRONG, Kenji FUJITA
Filed: 19 Nov 19
Utility
Subcutaneous Dosage and Administration of ANTI-C5 Antibodies for Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
23 Dec 21
Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) subcutaneously according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule).
Lori Volles, Rajendra Pradhan, Douglas L. Sheridan, Marc Vallee, Xiang Gao
Filed: 30 Oct 19
Utility
Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody
21 Dec 21
The present disclosure relates to, inter alia, a method of treating age-related macular degeneration (AMD) in a patient, comprising administering an effective amount of a C5 inhibitor or a C5a inhibitor.
Yi Wang, Barbel Rohrer
Filed: 6 Oct 16